58778 Federal Register / Vol. 65, No. 191 / Monday, October 2, 2000 / Notices

Isolation of Cellular Material Under

Microscopic Visualization

Liotta et al. (NCI)

Serial No. 08/203,780 filed 01 Mar 1994,

issued as U.S. Patent No. 5,843,644;

Serial No. 08/544,388 filed 10 Oct

1995, issued as U.S. Patent No.

5,843,657; Serial No. 08/882,699 filed

25 Jun 1997; Serial No. 08/925,894

filed 08 Sep 1997, issued as U.S.

Patent No. 6,010,888; Serial No. 09/

388,805 filed 02 Sep 1999

Licensing Contact: J. P. Kim; 301/496–

7056 ext. 264; e-mail:

kimj@od.nih.gov

The present technology provides

methods and devices for the isolation

and analysis of cellular samples on a

molecular or genetic level. More

particularly, the invention relates to

methods and devices for the

microdissection, for example, utilizing

laser capture microdissection (LCM),

and the diagnosis and analysis of

cellular samples which may be used in

combination with a number of different

technologies that allow for analysis of

enzymes, antigens, mRNA, DNA, and

the like from pure populations or

subpopulations of particular cell types.

Nucleic Acid Constructs Containing

HIV Genes with Mutated Inhibitory/

Instability Regions and Methods of

Using Same

George N. Pavlakis, Barbara K. Felber

(NCI)

Serial No. 07/858,747 filed 27 Mar 1992;

U.S. Patent 5,972,596 issued 26 Oct

1999; U.S. Patent 5,965,726 issued 12

Oct 1999; Serial No. 09/414,117 filed

08 Oct 1999; PCT/US93/02908

Licensing Contact: Carol Salata; 301/

496–7735 ext. 232; e-mail:

salatac@od.nih.gov

This invention describes methodology

for modifying the inhibitory/instability

sequences (INS) of mRNA by making

multiple nucleotide substitutions

without altering the coding capacity of

the mRNA of interest. Mutating INS

allows for or increases the expression of

genes that would otherwise have not

been expressed or would have been

poorly expressed because of the INS

normally present on the mRNA

transcript. This novel approach also

improves the stability of the mRNA.

These methods can be used to increase

the production of protein from many

genes producing, for example, growth

hormone, interferons, interleukins, and

HIV Gag and env. DNA constructs are

described which encode Gag protein

which is highly expressed and does not

require HIV rev for production. Thus it

is a potentially useful HIV DNA vaccine.

Assays have also been developed to

facilitate detection of the boundaries of

INS sequences of any mRNA.

Dated: September 20, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–25175 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESS: Licensing information and

copies of the U.S. patent application

listed below may be obtained by

contacting Susan S. Rucker, J.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7056 ext. 245; fax: 301/402–0220;

e-mail: ruckers@od.nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive a copy of the

patent application.

HGF–SF Monoclonal Antibody

Combinations

B Cao, S Koochekpou, M Oskarsson, D

Bjurickovic, M Fivash, R Fisher and

GR Vande Woude (NCI)

Serial No. 60/164,173 filed 09 Nov 1999

The invention described and claimed

in this application relates to a

composition which comprises a

combination of two or more antibodies

which specifically bind one or more

epitopes of the growth factor known as

hepatocyte growth factor/scatter factor

(HGF/SF) which is able to inhibit HGF/

SF signaling. In particular, the

antibodies which specifically bind to

HGF/SF are monoclonal antibodies.

Hepatocyte Growth Factor (HGF)

activates migration and proliferation of

endothelial cells and is angiogenic,

acting through the tyrosine kinase

receptor encoded by the Met

protooncogene. In addition, HGF/SF

displays a unique feature in inducing

‘‘branching morphogenesis’’, a complex

program of proliferation and

motogenesis in a number of different

cell types. Moreover, HGF is involved in

the invasive behavior of several tumor

cells both in vivo and in vitro. This

combination of antibodies may be useful

in drug screening assays, detection of

HGF/SF expression or activity or in

treating HGF/SF related diseases such as

cancer.

Dated: September 21, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer Office of Technology Transfer

National Institutes of Health.

[FR Doc. 00–25176 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Notice of Meeting: Chronic Fatigue

Syndrome Coordinating Committee

In accordance with section 10(a) of

the Federal Advisory Committee Act, as

amended (5 U.S.C., Appendix 2), notice

is hereby given of a meeting of the

Chronic Fatigue Syndrome Coordinating

Committee.

Name: Chronic Fatigue Syndrome

Coordinating Committee

Time and Date: Wednesday, October 25,

2000, from 9 a.m. to 4:30 p.m.

Place: Hubert H. Humphrey Building,

Room 800, 200 Independence Avenue, SW.,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available. The meeting room will

accommodate approximately 100 people.

Individuals who plan to attend and need

special assistance, such as sign language

interpretation or other reasonable

accommodations, should notify the Contact

Person listed below in advance of the

meeting.

Notice: In the interest of security, the

Department has instituted stringent

procedures for entrance to the Hubert H.

Humphrey Building by non-government

employees. Thus, persons without a

government identification card will need to

provide a photo ID and must know the

subject and room number of the meeting in

order to be admitted into the building.

Visitors must use the Independence Avenue

entrance.

Purpose: The Committee is charged with

providing advice to the Secretary, the

Assistant Secretary for Health, and the

Commissioner, Social Security

Administration (SSA), to assure interagency

coordination and communication regarding

chronic fatigue syndrome (CFS) research and

Federal Register / Vol. 65, No. 191 / Monday, October 2, 2000 / Notices 58779

other related issues; facilitating increased

DHHS and agency awareness of CFS research

and educational needs; developing

complementary research programs that

minimize overlap; identifying opportunities

for collaborative and/or coordinated efforts in

research and education; and developing

informed responses to constituency groups

regarding DHHS and SSA efforts and

progress.

Matters To Be Discussed: The meeting will

include a discussion of the CFS State of the

Science Conference held October 23–24,

2000; progress report from the Name Change

Working Group; update on current Federal

activities; and identification of areas for

future focus for the CFSCC. Public comments

will be received at the meeting on two topics

of interest to the Committee: (1) Lack of

access to social services and (2) insensitive

medical care. Persons wishing to make oral

comments on these topics either in person or

via video should notify the contact person

listed below no later than COB on October

17, 2000. Five minutes will be allotted for

each statement; both printed and electronic

copies are requested for the record.

Contact Person for More Information:

Janice C. Ramsden, Executive Secretary,

CFSCC, Office of the Principal Deputy

Director, NIH, Building 1, Room 333, 1

Center Drive, MSC 0159, Bethesda, Maryland

20892–0159, e-mail jr52h@nih.gov or

telephone 301–496–0959.

Dated: September 22, 2000.

LaVerne Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–25163 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and

Infectious Diseases; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The contract proposals and

the discussions could disclose

confidential trade secrets or commercial

property such patentable material, and

personal information concerning

individuals associated with the contract

proposals, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Allergy and Infectious Diseases Special

Emphasis Panel.

Dates: October 30, 2000.

Time: 8:30 AM to 4:00 PM.

Agenda: To review and evaluate contract

proposals.

Place: Holiday Inn, 5520 Wisconsin

Avenue, Chevy Chase, MD 20815.

Contact Person: Edward W. Schroder, PHD,

Scientific Review Administrator, Scientific

Review Program, Division of Extramural

Activities, NIAID, NIH, Room 2156, 6700–B

Rockledge Drive, MSC 7610, Bethesda, MD

20892–7610, 301–496–2550.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.855, Allergy Immunology,

and Transplantation Research; 93.856,

Microbiology and Infectious Diseases

Research, National Institutes of Health, HHS)

Dated: September 21, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–25156 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and

Infectious Diseases; Notice of Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given on the following

meeting.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Microbiology and

Infectious Diseases Research Committee.

Dates: October 4–5, 2000.

Open: October 4, 2000, 9:00 AM to 10:00

AM.

Agenda: Reports from various Institute

staff.

Place: One Washington Circle Hotel,

Conference Center, One Washington Circle,

DC 20037.

Closed: October 4, 2000, 9:00 AM to

adjournment on October 5, 2000.

Agenda: To review and evaluate grant

applications.

Place: One Washington Circle Hotel,

Conference Center, One Washington Circle,

DC 20037.

Contact Person: Gary S. Madonna, PhD,

Scientific Review Administrator, Scientific

Review Program, Division of Extramural

Activities, NIAID, NIH, Room 2217, 6700–B

Rockledge Drive, MSC 7610, Bethesda, MD

20892–7610, 301–496–2550.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.855, Allergy, Immunology,

and Transplantation Research; 93.856,

Microbiology and Infectious Diseases

Research, National Institutes of Health, HHS)

Dated: September 21, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–25157 Filed 9–29–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and

Other Communication Disorders;

Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Deafness and Other Communications

Disorders Special Emphasis Panel.

Dates: November 14–15, 2000.

Time: 8 AM to 12 PM.

Agenda: To review and evaluate grant

applications.

Place: The Virginian Suites, 1500

Arlington Blvd., Arlington, VA 22209.

Contact Person: Stanley C. Oaks, Jr., PhD,

Scientific Review Branch, Division of

Extramural Research, Executive Plaza South,

Room 400C, 6120 Executive Blvd., Bethesda,

MD 20892–7180, 301–496–8683.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.173, Biological Research